{"entity":{"id":"nct05186974","kind":"trial","name":"Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)","aka":["EVOKE-02"],"tldr":"A phase 2 trial of Sacituzumab govitecan, Pembrolizumab, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by Gilead Sciences, active and no longer recruiting.","summary":"Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) is a phase 2 interventional study registered as NCT05186974 by Gilead Sciences, with 193 participants enrolled, started 2022-05-30 and due to reach its primary completion in 2027-03. Interventions recorded: Sacituzumab Govitecan-hziy (SG), Pembrolizumab, Carboplatin, Cisplatin. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05186974","url":"https://clinicaltrials.gov/study/NCT05186974"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":["adc","topoisomerase-inhibitors"],"targets":[],"drugs":["sacituzumab-govitecan","pembrolizumab","carboplatin","cisplatin"],"companies":["gilead"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-nct05186974-j-thorac-oncol-2026"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05186974","phase":"2","setting":"An Open-label, Multicenter, Phase 2 Study of Sacituzumab Govitecan Combinations in First-line Treatment of Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Without Actionable Genomic Alterations","sponsor":"Gilead Sciences","started":"2022-05-30","startedType":"actual","enrolled":193,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05186974/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/"}],"company":[{"id":"gilead","kind":"company","name":"Gilead Sciences (incl. Kite)","route":"/companies/gilead/"}],"paper":[{"id":"paper-nct05186974-j-thorac-oncol-2026","kind":"paper","name":"First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS Less Than 50% and More Than or Equal to 50% Cohorts of the EVOKE-02 Study","route":"/key-papers/paper-nct05186974-j-thorac-oncol-2026/"}]}}